Condition
DTC - Differentiated Thyroid Cancer
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07287748Phase 1RecruitingPrimary
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
NCT05007093Phase 2Active Not RecruitingPrimary
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
NCT06405217Not ApplicableRecruitingPrimary
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Showing all 3 trials